Document:

AMENDMENT
TO PROMISSORY NOTE

WHEREAS,
American Boarding Company, a Delaware corporation, (“Maker”) has issued that certain Promissory Note to Jenny Su in
the principal amount of $10,000 on December 10, 2014 (the “Note”),

NOW,
THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

	All
provisions set forth in the Note providing that any amounts due under the Note are convertible to capital stock of the Maker are
hereby deleted. The Note shall not be convertible to common stock, or any other class of capital stock, of the Maker.
	All
other terms of the Note not specifically modified by this Amendment shall remain in full force and effect.

/s/
Jenny Su

Jenny
Su 

American
Board Company

 

By:
/s/ Reza Noorkayhani

Reza
Noorkayhani, President and CEO***OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION

CONFIDENTIAL TREATMENT REQUESTED

 

PATENT
& Technology LICENSE AGREEMENT

AGT.
No. A2013-2080

 

This Patent & Technology License
Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).

 

No binding agreement between
the Parties will exist until this Patent & Technology License Agreement has been signed by both Parties.  Unsigned drafts
of this Patent & Technology License Agreement shall not be considered offers.

 

Background

 

Licensor owns, controls and/or
has the right to sublicense the Licensed Subject Matter (defined in Exhibit A). Licensee desires to secure the right and license
to use, develop, manufacture, market, and commercialize the Licensed Subject Matter. Licensor desires to have the Licensed Subject
Matter developed and used for the benefit of Licensee, the inventors, Licensor, and the public.

 

NOW, THEREFORE, in consideration
of the mutual covenants and premises herein contained, the Parties hereby agree as follows:

 

The Terms and Conditions of Patent
& Technology License attached hereto as Exhibit A are incorporated herein by reference in their entirety (the “Terms
and Conditions”). The Commercialization Plan attached hereto as Exhibit B is incorporated herein by reference in its entirety
(the “Commercialization Plan”). In the event of a conflict between provisions of this Patent & Technology License
Agreement and the Terms and Conditions, the provisions in this Patent & Technology License Agreement shall govern. Unless
defined in this Patent & Technology License Agreement, capitalized terms used in this Patent & Technology License Agreement
shall have the meanings given to them in the Terms and Conditions.

 

The section numbers used in the
left hand column in the table below correspond to the section numbers in the Terms and Conditions.

 

	 	1.   Definitions

	 	Effective
    Date	September
    6 , 2013
	Licensor	Ohio
    State Innovation Foundation, with an address at 1524 North High Street, Columbus, OH 43201.
	Licensee 
	MicroLin
    Bio, Inc., a corporation, with its principle place of business at 302A West 12th Suite 114, New York, NY 10014
	Contract
    Year and Contract Quarters	 

        x
Cntract Year is 12-month period
ending on December 31 and Contract Quarters are 3-month periods ending on March 31, June 30, Sept. 30, Dec. 31

          

	Territory
    	Worldwide

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 1 of 39

    	Exhibit 10.4

    

  

	 	Field of Use

         
	Exclusive Field of use
        for the diagnosis, prognosis and therapy/treatment of lung cancer.

         

	 	 	Patent
Rights/Technology Rights 

        [See Exhibit C for
        individual patent application and patent information]

        

	 	App. No./

    Date of Filing	Title	Inventor(s)	Jointly

    Owned?

    (Y/N; if Y,

    with whom?)	Countries	Prosecution

    Counsel
	 	PCT/US2007/000159

         03/03/2007

         [2006-138]

         

         
	MicroRNA-Based
    Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers	C. Croce

        S. Volinia

        G. Calin

	x
    No	US

        CA

        AU

        CN

        JP

        HK

        EU

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2007/000103

        01/03/2007

        [2006-008]

	MicroRNA-Based
    Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer	C. Croce

        G. Calin

        C. Harris

	x
        Yes w/ the National Institutes of Health

         

         

         

        [See section 20.1]

         
	US

        CA

        JP

        AU

        CN

        EU

	MacMillan,
    Sobanski, and Todd LLC
	 	PCT/US2010/057758

        11/23/2010

        [2010-079]

	Material
    and Methods Useful for Affecting Tumor Cell Growth, Migration, and Invasion	C. Croce

        G. Nuovo

        F. Pichiorri

        G. Romano

        P. Secchiero

        S. Suh

        C. Taccioli

        M. Acunzo

        H. Alder

        G. Condorelli

        G. Di Leva

        P. Gasparini

        M. Garofalo

        A. Gonelli

        A. Ngankeu

	x
        NO

         

         

         
	US

        CA

        JP

        AU

        CN

        EU

	MacMillan,
    Sobanski, and Todd LLC

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 2 of 39

    	Exhibit 10.4

    

  

	 	PCT/US2008/072081
        08/04/2008

        [2007-028]

	Ultraconserved
    Regions Encoding ncRNAs 	C. Croce

	x
    No	US

        CA

        JP

        AU

        CN

        EP

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2011/029348
        03/22/2011

        [2010-126]

	Materials
    and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155	C. Croce

        N. Valeri

	x
    No	US

        CA

        JP

        AU

        CN

        EP

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2008/071532

        07/30/2008

        [2007-159]

	Methods
    for Reverting Methylation by Targeting DNMT3A and DNMT3B	C.
    Croce	x
    No	US

        CA

        JP

        AU

        CN

        EP

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2008/081294

        10/27/2008

        [2007-030]

	Methods
    of Identifying Fragile Histidine Triad (FHIT) Interaction and Uses Thereof	C.
    Croce	x
    No	US

        CA

        JP

        AU

        CN

        EP

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2012/069484

        12/13/2012

        [2012-066]

	Methods
    and Compositions Related to miR-21 and miR-29a, Exosome Inhibition and Cancer Mestastsis	C. Croce

        M. Fabbri

	x
    No	US

        CA

        JP

        AU

        CN

        EP

	MacMillan,
    Sobanski, and Todd LLC
	PCT/US2012/068736

        12/10/2012

        [2012-111]

	miRNAs
    Useful to Reduce Lung Cancer Turmorigenesis and Chemotherpay Resistance and Related Compositions and Methods	C. Croce

        M. Garofalo

	x
    No	US

        National

        Phase
        Approaching

          
	MacMillan,
    Sobanski, and Todd LLC

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 3 of 39

    	Exhibit 10.4

    

  

	 	PCT/US2012/028016

        03/07/2012

        [2011-137]

	Mutator
    Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer	C. Croce

        S. Costinean

        H. Alder

        J. Michaille

        E. Tili

        S. Volinia

        D.
        Wernicke-Jameson

	x
    No	US

        National
        Phase Approaching

	MacMillan,
    Sobanski, and Todd LLC
	61/704,542

        09/23/2012

        [2013-072]

	Use
    of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation	C. Croce

        G. Romano

	x
    No	US

        CA

	MacMillan,
    Sobanski, and Todd LLC
	USPTO Entity Status
        as of Effective Date

         
	Check one box:

        

        x
        Small

         

	 	 	 	 	 	 	 	 

	 	2.4.  Diligence
    Milestones

	 

         

         
	Milestones
    and deadlines	Milestone
    Events	Deadlines
	1.  Completion
    of Commercialization Plan for use of Licensed Product or Licensed Service for early diagnosis of lung cancer.	***
	2.
    Hiring of experienced executive management, sales, and research team for the commercialization of Licensed Product or Licensed
    Service.  	***
	3.  External
    funding or equity financing of greater than or equal to $500,000 received by Licensee for the purpose of advancing Licensed
    Products and/or Licensed Service.	***
	4.   CLIA
    validation of first Licensed Product or Licensed Service for the diagnosis and/or prognosis of lung cancer. Milestone extension
    option and fees referenced in Section 20.3 may be applied to this Milestone.	***
	5.
    Execute a Sublicense Agreement for the development and/or establishment of a research development program for lung cancer
    therapeutics. Milestone extension option and fees referenced in Section 20.3 may be applied to this Milestone.	***
	6.
Complete financing in which Licensee receives $10,000,000 or greater for the purpose of advancing Licensed Product and/or Licensed
Service. Milestone extension option and fees referenced in Section 20.3 may be applied to this Milestone.

                                                                                
	***

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 4 of 39

    	Exhibit 10.4

    

  

 

	 	 	7.  Establishment
    of clinical insurance reimbursement for the diagnosis and/or prognosis of lung cancer. Milestone extension option and fees
    referenced in Section 20.3 may be applied to this Milestone.	***
	8.  First
    Sale in the United States of America of the first Licensed Product or Licensed Service for the diagnosis and/or prognosis
    of lung cancers. Milestone extension option and fees referenced in Section 20.3 may be applied to this Milestone.	***
	9. First Sale in any country
        outside of the United States of America of the first Licensed Product or Licensed Service for the diagnosis and/or prognosis
        of lung cancer. Milestone extension option and fees referenced in Section 20.3 may be applied to this Milestone.

          
	***

	 	3.  Compensation

	3.1(a)	Patent
                                         expenses due upon Effective Date

          

        (See Section 20.1)

         
	 	Amount	based
    on invoices received as of:
	Tech
    ID 2006-138	$355,066.061
    	August
    29, 2013  
	Tech
    ID 2006-008	$238,745.45  	August
    29, 2013
	Tech
    ID 2007-159	$116,113.80  	August
    29, 2013
	Tech
    ID 2007-028	Costs
    already accounted for in Agreement# A2013-2069 having an Effective Date of September 6, 2013 between the parties.	August
    296, 2013, 2013
	Tech
    ID 2010-126	Costs
    already accounted for in Agreement# A2013-2069 having an Effective Date of September 6, 2013 between the parties.	August
    29, 2013, 2013
	Tech
    ID 2010-079	$66,105.78
    	August
    29, 2013 
	Tech
    ID 2007-030	Costs
    already accounted for in Agreement# A2014-0165 having an Effective Date of September 6,2013between the parties. 	 August
    29, 2013
	Tech
    ID 2012-066	Costs
    already accounted for in Agreement# A2014-0165 having an Effective Date of September 6, 2013 between the parties.	August
    29, 2013 
	Tech
    ID 2011-137	Costs
    already accounted for in Agreement# A2014-0165 having an Effective Date of September 6, 2013between the parties.	August
    29, 2013

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 5 of 39

    	Exhibit 10.4

    

  

	 	 	Tech
    ID 2006-009	Costs
    already accounted for in Agreement# A2014-064 having an Effective Date of September 6, 2013 between the parties.	August
    29, 2013
	Tech
    ID 2012-111	$12,109.00
    	August
    29, 2013 
	Tech
    ID 2013-072	$3,835.00	August
    29, 2013 
	Total	$791,975.09
    	 

	3.1(b)	Milestone
        fees

         
	Milestone
    Events	Milestone
    Fees
	1.  Completion
    of Commercialization Plan for use of Licensed Product or Licensed Service for early diagnosis of lung cancer.	***
	2.
    Hiring of experienced executive management, sales, and research team for the commercialization of Licensed Product or Licensed
    Service.  	***
	3.  External
    funding or equity financing of greater than or equal to $500,000 received by Licensee for the purpose of advancing Licensed
    Products and/or Licensed Service.	***
	4.   CLIA
    validation of first Licensed Product or Licensed Service for the diagnosis and/or prognosis of lung cancer.	***
	5.
    Execute a Sublicense Agreement for the development and/or establishment of a research development program for lung cancer
    therapeutics.	 (Associated
fees referenced in Sections 3.1(e) and/or 20.4)

	6.
    Complete financing in which Licensee receives $10,000,000 or greater for the purpose of advancing Licensed Product and/or
    Licensed Service.	***
	7.  Establishment
    of clinical insurance reimbursement for the diagnosis and/or prognosis of lung cancer.	***
	8.  First
    Sale in the United States of America of the first Licensed Product or Licensed Service for the diagnosis and/or prognosis
    of lung cancers.	***
	9.
    First Sale in any country outside of the United States of America of the first Licensed Product or Licensed Service for the
    diagnosis and/or prognosis of lung cancer.	***

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 6 of 39

    	Exhibit 10.4

    

  

	3.1(c)	Upfront
    Fee	$5,000 due on Effective
        Date

        $95,000 due on or before
May 31, 2014 

	3.1(d)	License
                                         Maintenance Fees

         
	$10,000 due on May 31,
        2015

        $25,000
due on May 31, 2016

        

        $50,000 due on May 31,
        2017

        

	3.1(e)	Sublicense
    Fees 	*** of Non-Royalty Sublicensing
        Consideration for diagnostics and prognostics.

         

        *** of Non-Royalty Sublicensing
        Consideration for therapeutics.

         

	3.1(f)	Assignment
    fee	For the Contract Year
        ending ***, the greater of *** (USD) or *** of Gross Consideration of the total transaction value received by Licensee
        for any transaction that includes the assignment or transfer of any portion of this Agreement.

          

        For any Contract Year
        thereafter, the greater of *** (USD) or *** of Gross Consideration of the total transaction value received by Licensee
        for any transaction that includes the assignment or transfer of any portion of this Agreement. Assignments shall include
        assignments or transfers of the Agreement as part of a corporate reorganization, consolidation, merger or sale of substantially
        all of the assets or any other change of control

	3.2	Running
    royalty rate (applies to Sales by Licensee, Affiliates and Sublicensees)	(a)  Licensed
    Products and Licensed Services Covered By any claim or claims included within the Patent Rights 	***
	(b) Licensed Products
        and Licensed Services not Covered By any claim or claims included within the Patent Rights

          
	***
	3.3	Minimum
    royalty 	*** for Contract Year
        ending ***

        

        *** for Contract Year ending
        ***

        *** per each subsequent
Contract Year thereafter. 

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 7 of 39

    	Exhibit 10.4

    

  

	 	18.   Contact
    Information

	 	Licensee
    Contacts	Licensor
    Contacts
	Contact for Notice:

        Attn: Joseph
        Hernandez

        

        302A West 12th
Suite 114 

        New York, NY
        10014

        Phone: 646-707-2937 

        Email: hernandez_joe@yahoo.com

         

        Accounting contact:

        Attn: Joseph
Hernandez

        302A West 12th
Suite 114 

        New York, NY
10014

        Phone: 646-707-2937

        Email: hernandez_joe@yahoo.com

          

        Patent prosecution
contact:

        Attn: Joseph
Hernandez

        302A West 12th
Suite 114

        New York, NY
10014

        Phone: 646-707-2937

        Email: hernandez_joe@yahoo.com
	Contact for Notice:

        Attn: President

         

        1524 North High Street

        Columbus, Ohio 43201

        Fax: 614-292-8907

        Phone: 614-292-1315

        E-mail: techlicensing@osu.edu

         

        Payment and reporting
        contact:

        Checks payable to “Ohio
        State Innovation Foundation”

        Attn: Accounting/Compliance

        1524 North High Street

        Columbus, Ohio 43201

        Fax: 614-292-8907

        Phone: 614-292-1315

        Email: OSIFCompliance@osu.edu

         

        Patent prosecution contact:

        Attn: Catherine
Martineau

        MacMillan, Sobanski
, & Todd, LLC ; Patent, Trademark, Copyright and Intellectual Property Law

        One Maritime
Plaza, Fifth Floor

        720 Water Street

        Toledo, Ohio
43604-1853

        419-255-5900
(voice)

        419-255-9639
(fax)

        E-mail:
martineau@mstfirm.com

        Internet:
        http//www.mstfirm.com

         

	 	For
    Licensor Administrative Purposes Only

	Changes
    to Standard Form Terms and Conditions	 	There have not been any
        revisions to Licensor’s standard form Terms and Conditions , except for revisions to the following sections: 7

         

 

20. Special Provision.
The Parties hereby agree to the following special provisions set forth in this Section 20 with respect to this Patent & Technology
License Agreement.

 

Section
20.1 Inter-Institutional Agreement. Pursuant to an Inter-Institutional Agreement (NIH
reference number L-003-2009) having an effective date of October 23, 2008 between Licensor and National
Institutes of Health (NIH), NIH has granted Licensor the ability to grant license rights in the patent indicated in Section 1
as jointly owned by Licensor and NIH.

 

Section 20.2 Payment Schedule
for Past Patent Expenses. Licensee will repay the past patent expenses referenced in Section 3.1(a) above upon the earlier
of: (1) the payment due dates on the following schedule (shown below); or (2) Licensee has cumulative external funding (any combination
of government grant, government contract, or private equity) of at least $10,000,000. In the event that $10,000,000 of external
funding is obtained by Licensee, all unpaid amounts of past patent expenses shall become immediately due and payable to Licensor.
The payments below include interest at the rate of 3.50% per annum. Should this Agreement be terminated, all patent expenses
are immediately due and payable by Licensee to Licensor.

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 8 of 39

    	Exhibit 10.4

    

 

 

	Pmt
 No.	 	Payment
 Date	 	Beginning
 Balance	 	 	Scheduled
 Payment	 	 	Total
 Payment	 	 	Principal	 	 	Interest	 	 	Ending
 Balance	 
	1	 	10/31/2013	 	$	791,975.09	 	 	$	25,000.00	 	 	$	25,000.00	 	 	$	11,140.44	 	 	$	13,859.56	 	 	$	780,534.65	 
	2	 	12/31/2013	 	$	780,534.65	 	 	$	25,000.00	 	 	$	25,000.00	 	 	$	11,335.39	 	 	$	13,664.61	 	 	$	769,199.21	 
	3	 	7/31/2014	 	$	769,199.21	 	 	$	25,000.00	 	 	$	25,000.00	 	 	$	11,539.01	 	 	$	13,460.99	 	 	$	757,660.20	 
	4	 	12/31/2014	 	$	757,660,20	 	 	$	25,000.00	 	 	$	25,000.00	 	 	$	11,740.94	 	 	$	13,259.05	 	 	$	745,919.26	 
	5	 	6/30/2015	 	$	745,919.26	 	 	 	95,084.92	 	 	 	95,084.92	 	 	$	91,821.52	 	 	$	3,263.40	 	 	$	654,097.74	 
	6	 	9/30/2015	 	$	654,097.74	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	92,223.24	 	 	$	2,861.68	 	 	$	561,874.50	 
	7	 	12/31/2015	 	$	561,874.50	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	92,626.72	 	 	$	2,458.20	 	 	$	469,247.78	 
	8	 	3/31/2016	 	$	469,247.78	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	93,031.96	 	 	$	2,052.96	 	 	$	376,215.83	 
	9	 	6/30/2016	 	$	376,215.83	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	93,438.97	 	 	$	1,645.94	 	 	$	282,776.85	 
	10	 	9/30/2016	 	$	282,776.85	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	93,847.77	 	 	$	1,237.15	 	 	$	188,929.08	 
	11	 	12/31/2016	 	$	188,929.08	 	 	$	95,084.92	 	 	$	95,084.92	 	 	$	94,258.35	 	 	$	826.56	 	 	$	94,670.73	 
	12	 	3/31/2017	 	$	94,670.73	 	 	$	95,084.92	 	 	$	94,670.73	 	 	$	94,256.55	 	 	$	414.18	 	 	$	0.00	 

 

Each of the
Licensed Patents listed in a separate row in Section 1 shall constitute a single patent family.  The past patent expenses
set forth in Section 3.1(a) are separated out and each entry corresponds to a particular single patent family identified in Section
1.  Certain of the past patent expenses for a single patent family may also be covered by one or more separate agreements
between Licensor and Licensee (a “Multi-Covered Patent Expense”).  Licensor does not intend for Licensee to pay
double for Multi-Covered Patent Expenses.

 

Section
20.3 Milestone Extension Option. Licensee shall have the one-time option to extend the deadlines for those
Milestone Events specified in said Section 2.4 by three (3) months by paying a milestone extension fee of *** for each such extension.
This option may only be exercised at a time when Licensee is in compliance with all of its obligations under the Agreement, including
having met all milestones with deadlines prior to the date such notice is given (without giving effect to the extension resulting
from the exercise of such option). In order to exercise this option, Licensee must provide Licensor written notice of its exercise
of this option accompanied by payment of the milestone extension fee. Such notice must contain an affirmation from the Licensee
that it is in compliance with all of its obligations under the Agreement, that it has and is currently using commercially reasonable
efforts to implement the Commercialization Plan and Actively Commercialize Licensed Products or Licensed Services and that it
reasonably expects to meet the milestone deadlines as extended by the exercise of such option.

 

Section
20.4 Therapeutic Research and Development. Licensee shall launch a research and development program for the licensed therapeutic
rights pursuant to the therapeutic milestone events and fees outlined below, unless Licensee executes a Sublicense Agreement as
set forth in Milestone 5 in section 2.4 above. Should Licensee not execute a Sublicense Agreement as set forth in Milestone 5,
Licensee shall pay a fee of *** to the Licensor and provide a detailed Commercialization Plan for the licensed therapeutic rights
to Licensor within forty-five days of the Deadline for Milestone 5.

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 9 of 39

    	Exhibit 10.4

    

 

	Therapeutic Milestone Events	Deadlines	Therapeutic Milestone Fees
	1.    In-license
    acquisition and/or development of therapeutic delivery platform	***	***
	2.    Regulatory
    Approval of IND filing by Regulatory Authority.  	***	***
	3.    Dosing
    of first patient in a Regulatory Authority-approved Phase I Clinical Trial of Licensed Product	***	***
	4.    Dosing
    of first patient in an  Regulatory Authority-approved Phase II Clinical Trial of Licensed Product	***	***
	5.    Dosing
    of first patient in a Regulatory Authority-approved  Phase III Clinical Trial of Licensed Product	***	***
	6.    Regulatory
    Approval of Licensed Product in a major licensed country (e.g. US, EU country, or JP).	***	***
	7.    Launch
    of Licensed Product in a major licensed country (e.g. US, EU country, or JP).	***	***
	8.    Regulatory
    Approval of Licensed Product in a non-major licensed country. (e.g. CA, CN, or AU)	***	***
	9.    Launch
    of Licensed Product in a non-major licensed country. (e.g. CA, CN, or AU)	***	***

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 10 of 39

    	Exhibit 10.4

    

 

Section
20.5 Therapeutic Research and Development Sublicense. Should Licensee sublicense the licensed therapeutic and/or treatment
rights, Licensee shall require milestones at least as stringent as those outlined in section 20.4 above.

 

Section
20.6 Additional CLIA Product Launch. For each subsequent CLIA validation of a Licensed Product or Licensed Service
for the diagnosis and/or prognosis of lung cancer, which is launched after ***, Licensee shall pay Licensor ***.

 

Section
20.7 First Sale of Additional Products In United States of America. For each subsequent first Sale of
any new Licensed Product or Licensed Service for the diagnosis and/or prognosis of lung cancer, which are Sold or launched
after *** in the United States, Licensee shall pay Licensor a fee of ***.

 

Section
20.8  First Sale of Additional Products in any Non-U.S.A. Country For each subsequent first Sale of any
new Licensed Product or Licensed Service for the diagnosis and/or prognosis of lung cancer, Sold or launched after *** in any
country outside of the United States, Licensee shall pay Licensor a fee of ***.

 

Section
20.9 Identification of Sublicense Partners. For each Sublicensee brought to Licensee by Licensor that results in a
successful negotiation of a Sublicense Agreement, Licensee shall pay to Licensor *** within thirty (30) days of the execution
of said Sublicense Agreement.

 

Section
20.10 Termination Penalty. Should Licensee terminate this Agreement within two years of the Effective Date, Licensee shall
pay Licensor two million five hundred thousand ($2,500,000) dollars in addition to the requirements of section 7 below.

 

Section
20.11 Diagnostic & Prognostic Sublicense.  Licensee agrees to sublicense, nonexclusively and under reasonable terms,
the diagnostic and/or prognostic field of use covered only by the Patent Rights/Technology Rights identified in Section 1 as jointly
owned with the NIH and as referenced in section 20.1 above, to non-profit and commercial entities requesting such a sublicense
or referred by Licensor or NIH to Licensee.

 

21. No
Other Promises and Agreements; Representation by Counsel. Licensee expressly represents and warrants and does hereby state
and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this Patent &
Technology License Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not
relying upon any statement or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment
and has had the opportunity to be represented by legal counsel. Licensee hereby represents and warrants that Licensee understands
and agrees to all terms and conditions set forth in this Patent & Technology License Agreement and said Terms and Conditions.

 

    	{00182041-1}Licensee:  MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 11 of 39

    	Exhibit 10.4

    

 

22. Deadline
for Execution by Licensee. If this Patent & Technology License Agreement is executed first by the Licensor and is
not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms
and Conditions within thirty (30) days of the date of signature set forth under the Licensor’s signature below, then this
Patent & Technology License Agreement shall be null and void and of no further effect.

 

IN WITNESS WHEREOF, the Parties
hereto have caused their duly authorized representatives to execute this Patent & Technology License Agreement.

 

	LICENSOR: Ohio
    State Innovation Foundation	 	LICENSEE: MICROLIN BIO, INC.
	 	 	 	 	 
	By	/s/ Timothy R. Wright	 	By	/s/ Joseph Hernandez
	Timothy R. Wright	 	 	Joseph Hernandez
	Interim President	 	 	CEO and President
	Date	9/10/13	 	Date	9/10/13

 

    	{00182041-1}Licensee: MicroLin Bio, Inc.
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL

	Exclusive License (Life Sciences)
Page 12 of 39

    	 

    

 

EXHIBIT
A

Terms
and Conditions of Patent & Technology License

 

These Terms and Conditions of
Patent & Technology License (“Terms and Conditions”) are incorporated by reference into the Patent & Technology
License Agreement to which they are attached. All Section references in these Terms and Conditions shall be references to provisions
in these Terms and Conditions unless explicitly stated otherwise.

 

		1.	Definitions

 

“Actively
Commercialize” means having a commercially effective, reasonably funded (as compared to other similarly situated companies),
ongoing and active research, development, manufacturing, marketing and/or sales program directed toward obtaining regulatory approval,
production and/or Sales of Licensed Product(s) in a Field of Use in the Licensed Territory.

 

“Affiliate”
means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business
entity that is more than 50% owned by a business entity that owns more than 50% of Licensee.

 

“Agreement”
means collectively (i) these Terms and Conditions, and (ii) the Patent & Technology License Agreement.

 

“CLIA”
means Clinical Laboratory Improvement Amendments.

 

“Commercialization
Plan” means the written commercialization plan attached as Appendix B of the Patent & Technology License Agreement.

 

“Contract Quarter”
means the three-month periods indicated as the Contract Quarter in Section 1 of the Patent & Technology License Agreement,
or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement.

 

“Contract Year”
means the 12-month periods indicated as the Contract Year in Section 1 of the Patent & Technology License Agreement,
or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement.

 

“...Covered
By...” means a claim or claims within any pending or issued patent included in the Patent Rights claiming all,
a portion, or a component or step of a Licensed Process, Licensed Product, or Licensed Service.

 

“Effective
Date” means the date indicated as the Effective Date in Section 1 of the Patent & Technology License Agreement.

 

“Fair Market
Value” means the cash consideration an unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially
identical item sold in the same quantity, under the same terms, and at the same time and place.

 

“FDA”
means United States Food and Drug Administration.

 

“Field of Use”
means the field indicated as the Field of Use identified in Section 1 of the Patent & Technology License Agreement.

 

    	Licensee: [Company name]
Licensor: [Name]	CONFIDENTIAL
EXHIBIT A	Exclusive PLA (Physical Sciences)
Page 13 of 39

    	Exhibit 10.4

    

 

“Government”
means any agency, department or other unit of the United States of America or the State of Ohio.

 

“Gross Consideration”
means all cash and non-cash consideration (e.g., securities).

 

“IND”
means investigational new drug application, clinical study application, clinical trial exemption, or similar application or
submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance
with the requirements of such Regulatory Authority.

 

“Inventors”
(or singly, “Inventor”) means the inventors identified in the definition of Patent Rights/Technology Rights
in Section 1 of the Patent & Technology License Agreement.

 

“Licensed Process”
means a method, procedure, process, or other subject matter whose practice or use is Covered By any claim or claims included within
the Patent Rights or uses Technology Rights.

 

“Licensed Product”
means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination
or component thereof (i) whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within
the Patent Rights or incorporates any Technology Rights, or (ii) which is made using a Licensed Process or another Licensed Product.

 

“Licensed Service”
means performance of a service for any consideration using a Licensed Product, or the practice of a Licensed Process. For clarity,
research and development of Licensed Products by Licensee, its Affiliates, or a Sublicensee does not constitute a Licensed Service.

 

“Licensed Subject
Matter” means Patent Rights and/or Technology Rights

 

“Licensee”
means the Party identified as the Licensee in Section 1 of the Patent & Technology License Agreement.

 

“Licensor”
means the Party identified as the Licensor in Section 1 of the Patent & Technology License Agreement.

 

“Milestone
Fees” means all fees identified as Milestone Fees in Section 3.1(b) of the Patent & Technology License Agreement.

 

“Net Sales”
means the Gross Consideration from the Sale of Licensed Products, Licensed Processes, or Licensed Services less the following
items directly attributable to the Sale of such Licensed Products that are specifically identified on the invoice for such Sale
and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value
added, use and other taxes and government charges actually paid, excluding income taxes; (c) import and export duties actually
paid; (d) freight, transport, packing and transit insurance charges actually paid or allowed; and (e) other amounts actually refunded,
allowed or credited due to rejections or returns, but not exceeding the original invoiced amount.

 

“Non-Royalty
Sublicensing Consideration" means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee
in consideration of the grant of a sublicense under the Licensed Subject Matter (including, without limitation, license or option
or distribution fees, fees to maintain license rights, and bonus/milestone payments), but excluding amounts received as running
royalties, a profit share, or other revenue sharing based on Net Sales for which Licensor receives a running royalty under Section
3.2. For the avoidance of doubt, Non-Royalty Sublicensing Consideration shall not include bona fide: (a) running royalties received
by Licensee or an Affiliate based on Net Sales that are royalty-bearing to Licensor under Section 3.2, (b) purchase price for
Licensee’s stock or other securities not in excess of Fair Market Value, and (iii) amounts paid and used exclusively for
research and development of Licensed Products or Licensed Services by Licensee.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 14 of 39

    	Exhibit 10.4

    

 

“Patent &
Technology License Agreement” means the particular Patent & Technology License Agreement to which these Terms and
Conditions are attached and incorporated into by reference.

 

“Patent Rights” means the Licensor’s
rights in: (a) the patents and patent applications listed in Section 1 of the Patent & Technology License Agreement; (b) all
non-provisional patent applications that claim priority to any of the provisional applications listed in Section 1 of the Patent
& Technology License Agreement to the extent the claims of such non-provisional applications are entitled to claim priority
to such provisional applications; (c) all divisionals, continuations and continuations-in-part (excluding new matter and claims
containing new matter) of the non-provisional patent applications identified in (a) and (b), above to the extent that claims of
such continuations-in-part are entitled to claim priority to at least one of the patent applications identified in (a) or (b),
above; (d) all reissues, reexaminations, extensions, and foreign counterparts of any of the patents or patent applications identified
in (a), (b) or (c), above; and (e) any patents that issue with respect to any of the patent applications listed in (a), (b) ,
(c) or (d), above.  From time to time during the term of the Agreement, upon written agreement by both Parties, Licensee
and Licensor shall update the list of all patent applications and patents within the Patent Rights.

 

"Phase
I Clinical Trial" means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(a), designed
to provide evidence of safety and tolerability, metabolism, and pharmacological activity, the adverse experiences associated with
increasing doses, and, possibly, early evidence of efficacy of a Compound. Any clinical study in healthy volunteers is
a Phase I Clinical Study.

 

"Phase
II Clinical Trial" means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted
to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease
or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

 

"Phase
IIA Clinical Trial" means a relatively small Phase II Clinical Study designed to study the effectiveness of a particular
Product against placebo or other positive controls for a particular indication in patients with the disease or condition under
study, including narrowing the optimal dose, the potential utility, and common short-term side effects of the Product.

 

"Phase
IIB Clinical Trial" means a relatively longer and larger Phase II Clinical Study designed to study the effectiveness
of different doses of a particular Product against placebo or other positive controls for a particular Indication in patients
with the disease or condition under study, which is determined by the PDC to be a Phase IIB Clinical Study.

 

"Phase
III Clinical Trial" means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements
of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the
overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

 

“Prosecution
Counsel” means the law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as
of the Effective Date is identified in Section 1 of the Patent & Technology License Agreement.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 15 of 39

    	Exhibit 10.4

    

 

“Quarterly
Payment Deadline” means the day that is thirty (30) days after the last day of any particular Contract Quarter.

 

“Regulatory
Approval” means the approval needed by the Regulatory Authority for a particular national jurisdiction to market, Sell
and use a Licensed Product or Licensed Service in that national jurisdiction.

 

“Regulatory
Authority” means the governmental authority responsible for granting any necessary licenses or approvals for the marketing,
Sale and use of a Licensed Product or Licensed Service in a particular national jurisdiction, including without limitation FDA,
European Medicines Agency or Koseisho (i.e., the Japanese Ministry of Health and Welfare).

 

“Sell,
Sale or Sold” means any transfer or other disposition of Licensed Products or Licensed Services for which consideration
is received by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Services will be deemed completed
at the time Licensee or its Affiliate or its Sublicensee receives such consideration.

 

“Sublicense
Agreement” means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to
any third party any of the license rights granted to the Licensee under the Agreement.

 

“Sublicense
Fee” means the fee specified in Section 3.1(e) of the Patent & Technology License Agreement.

 

“Sublicensee”
means any entity to which an express sublicense has been granted under the Patent Rights and/or Technology Rights. For clarity,
a third party wholesaler or distributor who has no significant responsibility for marketing and promotion of the Licensed Product
or Licensed Services within its distribution territory or field (i.e., the third party simply functions as a reseller), and who
does not pay any consideration to Licensee or an Affiliate for such wholesale or distributor rights, shall not be deemed a Sublicensee;
and the resale by such a wholesaler or distributor shall not be treated as royalty bearing Net Sales by a Sublicensee provided
that a royalty is being paid by Licensee for the initial transfer to the wholesaler or distributor pursuant to Section 3.2. This
definition does not limit Licensee’s rights to grant or authorize sublicenses under the Agreement.

 

“Technology
Rights” means Licensor’s rights in technical information, know-how, processes, procedures, compositions, devices,
methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors while employed
at The Ohio State University (“OSU”) and within the Field of Use which are not Covered By any claim or claims included
within the Patent Rights, but which are either (1) directly related to the Tech ID listed in Section 1 of the Patent & Technology
License Agreement or (2) necessary for practicing inventions claimed in patents and/or patent applications listed in the definition
of Patent Rights whether outstanding, expired or abandoned.

 

“Territory”
means the territory so indicated as the Territory in Section 1 of the Patent & Technology License Agreement.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 16 of 39

    	Exhibit 10.4

    

 

		2.	License Grant and Commercialization

 

		2.1	Grant

                                         

		(a)	Licensor grants to Licensee a royalty-bearing
                                         exclusive license under Patent Rights to manufacture, have manufactured, distribute,
                                         have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products
                                         in the Field of Use in the Territory and to perform Licensed Services in the Field of
                                         Use in the Territory.

 

		(b)	Licensor grants to Licensee a royalty-bearing
                                         non- exclusive sublicense under Technology Rights to manufacture, have manufactured,
                                         distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed
                                         Products in the Field of Use in the Territory and to perform Licensed Services in the
                                         Field of Use in the Territory.

 

		(c)	This grant is subject to (i) the
                                         payment by Licensee to Licensor of all consideration required under the Agreement, (ii)
                                         any rights of, or obligations to, the Government as set forth in Section 11.2 (Government
                                         Rights), and (iii) rights retained by Licensor to:

 

		(1)	Publish the scientific findings
                                         from research related to the Patent Rights; and

 

		(2)	Use the Licensed Subject Matter
                                         for teaching, research, patient care, education, and other educationally-related purposes;
                                         and

 

		(3)	Grant
                                         rights to, and transfer material embodiments of, the Licensed Subject Matter to other
                                         academic institutions or non-profit research institutions for the purposes identified
                                         in clauses (1) and (2) above.

 

(d)          Licensor
reserves all rights not expressly granted in the Agreement including, but not limited to, any other licenses, implied or otherwise,
to any patents or other rights of Licensor, regardless of whether such patents or other rights are dominant or subordinate to
any rights expressly granted in the Agreement, or are required to exploit any rights expressly granted in the Agreement.

 

		2.2	Affiliates

Licensee may extend the
license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to the same
extent as Licensee.  For the sake of clarity, any specific reference to “Licensee” herein shall include such
Affiliate regardless of whether a specific reference to an “Affiliate” is made in such provision. Licensee agrees
to deliver such written agreement to Licensor within thirty (30) calendar days following execution.

 

		2.3	Sublicensing

Licensee has the right
to grant Sublicense Agreements under the Licensed Subject Matter consistent with the terms of the Agreement, subject to the following:

 

		(a)	A Sublicense Agreement shall not
                                         exceed the scope and rights granted to Licensee hereunder. Sublicensee must agree in
                                         writing to be bound by the applicable terms and conditions of the Agreement and shall
                                         indicate that Licensor is a third party beneficiary of the Sublicense Agreement. In the
                                         event of termination of this Agreement, continued sublicense rights shall be governed
                                         by Section 7.5(a) (Effect of Termination). Licensee has no right to grant a Sublicensee
                                         the right to grant further sub-Sublicense Agreements.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 17 of 39

    	Exhibit 10.4

    

 

		(b)	Licensee shall deliver to Licensor
                                         a true, complete, and correct copy of each Sublicense Agreement granted by Licensee,
                                         Affiliate or Sublicensee, and any modification or termination thereof, within thirty
                                         (30) days following the applicable execution, modification, or termination of such Sublicense
                                         Agreement. All Sublicense Agreements will be in English.

 

		(c)	Notwithstanding any such Sublicense
                                         Agreement, Licensee will remain primarily liable to Licensor for all of the Licensee’s
                                         duties and obligations contained in the Agreement, including without limitation the payment
                                         of running royalties due under Section 3.2 whether or not paid to Licensee by a Sublicensee.
                                         Any act or omission of a Sublicensee that would be a breach of the Agreement if performed
                                         by Licensee will be deemed to be a breach by Licensee. Each Sublicense Agreement will
                                         contain a right of termination by Licensee in the event that the Sublicensee breaches
                                         the payment or reporting obligations affecting Licensor or any other terms and conditions
                                         of the Sublicense Agreement that would constitute a breach of the Agreement if such acts
                                         were performed by Licensee.

 

		2.4	Diligent Commercialization

Licensee by itself or
through its Affiliates and Sublicensees will use diligent and commercially reasonable efforts to implement the Commercialization
Plan and to Actively Commercialize Licensed Products and/or Licensed Services (as applicable) in the Field of Use within the Territory.
Without limiting the foregoing, Licensee will

 

		(a)	maintain a bona fide, funded, ongoing
                                         and active research, development, manufacturing, regulatory, marketing or sales program
                                         (all as commercially reasonable) to make License Products and/or Licensed Services commercially
                                         available to the public as soon as commercially practicable, and

 

		(b)	fulfill the milestone events specified
                                         in Section 2.4 of the Patent & Technology License Agreement by the deadlines indicated
                                         therein.

 

If the obligations under
this Section 2.4 are not fulfilled, Licensor may treat such failure as a breach in accordance with Section 7.3(b).

 

		3.	Compensation

 

In consideration of
rights granted to Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not refundable
and are not creditable against other fees and royalties. Each payment will reference the Patent & Technology License Agreement
number and will be sent to Licensor’s payment and accounting contact in Section 18 (Notices) of the Patent & Technology
License Agreement.

 

		3.1	Non-Royalty Payments
due from Licensee

 

		(a)	Patent Expenses. Licensee
                                         will reimburse Licensor for the past patent expenses stated in Section 3.1(a) and Section
                                         20.1 of the Patent & Technology License Agreement within fifteen (15) days after
                                         the Effective Date. The stated amount is the current estimate for past patent expenses
                                         based on invoices received by the Licensor through the stated date. Licensee’s
                                         obligations to pay all past and future patent expenses pursuant to Section 6 (Patent
                                         Expenses and Prosecution) will not be limited by such amount.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 18 of 39

    	Exhibit 10.4

    

 

		(b)	Milestone Fees. Licensee
                                         will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License
                                         Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone
                                         events set forth in Section 3.1(b) of the Patent & Technology License Agreement are
                                         achieved.

 

		(c)	Upfront Fee. Licensee will
                                         pay the amount of the Upfront Fee set forth in Section 3.1(c) of the Patent & Technology
                                         License Agreement on the Effective Date.

 

		(d)	License Maintenance Fees.
                                         Licensee will pay license fees in the amounts set forth in Sections 3.1(d) of the Patent
                                         & Technology License Agreement in accordance with the stated schedule.

 

		(e)	Sublicense Fees. Licensee
                                         will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License
                                         Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

 

		(f)	Assignment Fee. Licensee
                                         will pay the assignment fee set forth in Section 3.1(f) of the Patent & Technology
                                         License Agreement within fifteen (15) days of the assignment of the Agreement.

 

		3.2	Royalties

Licensee will pay running
royalties on Net Sales in each Contract Quarter on or before the Quarterly
Payment Deadline for such Contract Quarter, as follows: (a) at the rate set forth
in Section 3.2(a) of the Patent & Technology License Agreement on Net Sales in each Contract Quarter for Licensed Products
and Licensed Services Covered By any claim or claims included within the Patent Rights;
and (b) at the rate set forth in Section 3.2(b) of the Patent & Technology License Agreement on Net Sales in each Contract
Quarter for Licensed Products and Licensed Services not Covered By any claim or claims included within the Patent Rights. No royalty shall be payable under this Section 3.2 with respect to (i) Sales to an Affiliate or Sublicensee of a particular
unit of Licensed Product that is used by such Affiliate or Sublicensee to perform a Licensed Service if Licensor is paid a royalty
on the Sale of such Licensed Service, (ii) the Sale of Licensed Products between or among Licensee, its Affiliates, and Sublicensees
for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty
Sublicensing Consideration.

 

		3.3	Minimum Royalties

If royalties paid to Licensor
do not reach the minimum royalty amounts stated in Section 3.3 of the Patent & Technology License Agreement for the specified
periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period
an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor.

 

		3.4	Non-cash Consideration

If Licensee receives or
anticipates receipt of non-cash consideration from Sales or Sublicenses, the manner in which Licensor will receive its compensation
under the Agreement with respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 19 of 39

    	Exhibit 10.4

    

 

		4.	Reports and Plans

 

The reports specified
in this Section 4 will be sent to Licensor’s payment and reporting contact identified in Section 18 (Notices) of the Patent
& Technology License Agreement. If Licensor requests to have information submitted in a particular format, Licensee will use
reasonable efforts to comply with such request.

 

		4.1	Quarterly Payment and
Milestone Reports

On or before each Quarterly
Payment Deadline, Licensee will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving such
particulars of the business conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by
Sublicensees and Affiliates to Licensee) during the preceding Contract Quarter under the Agreement as necessary for Licensor to
account for Licensee’s payments, including royalties, hereunder, even if no payments are due. The reports shall continue
to be delivered after the termination or expiration of the Agreement until such time as all Licensed Products permitted to be
Sold after termination or expiration have been Sold or destroyed. The report shall include:

 

		(a)	The name of the Licensee, the
                                         Patent & Technology License Agreement number, and the period covered by the report;

 

		(b)	The name of any Affiliates and
                                         Sublicensees whose activities are also covered by the report;

 

		(c)	Identification of each Licensed
                                         Product and Licensed Service for which any royalty payments have become payable;

 

		(d)	Net Sales segregated on a product-by-product
                                         basis, and a country-by-country basis, or an affirmative statement that no Sales were
                                         made. The report shall also itemize the permitted deductions from the Gross Consideration
                                         used to arrive at the resulting Net Sales, on a product-by-product and country-by-country
                                         basis;

 

		(e)	The applicable royalty rate;

 

		(f)	An affirmative statement of
                                         whether any milestones with deadlines in that Contract Quarter under Section 2.4 and
                                         any milestones under Section 3.1(b) were met or not, and the resulting Milestone Fee
                                         payable;

 

		(g)	Non-Royalty Sublicensing Consideration
                                         received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative
                                         statement that none was received;

 

		(h)	If any consideration was received
                                         in currencies other than U.S. dollars, the report shall describe the currency exchange
                                         calculations; and

 

		(i)	Any changes in accounting methodologies
                                         used to account for and calculate the items included in the report since the previous
                                         report.

 

		4.2	Annual Written Progress
Report and Commercialization Plan

Within forty five (45)
days following the end of each Contract Year, Licensee will deliver to Licensor a true and accurate signed written progress report,
that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to diligently commercialize Licensed
Products and Licensed Services, and (ii) Licensee’s development and commercialization plans with respect to Licensed Products
and Licensed Services for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees.
The report shall contain the following information to the extent relevant to the activities under the Agreement:

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 20 of 39

    	Exhibit 10.4

    

  

		(a)	The name of the Licensee, the
                                         Patent & Technology License Agreement number, the names of any Affiliates and Sublicensees,
                                         and the products and services being developed and/or commercialized;

 

		(b)	The progress toward completing
                                         and the plans for completing the applicable milestone events pursuant to Sections 2.4
                                         and 3.1(b); and

  

		(c)	The research and development
                                         activities, including status and plans for obtaining any necessary Regulatory Approvals,
                                         performed during the past year, and the plans for research and development activities
                                         for the next year.

 

		4.3	Government and Economic
Development Reporting

If Licensor requests,
Licensee will provide information for Licensor’s Government and economic development reporting purposes, including the following:

 

		(a)	Number and geographic location
                                         of new full-time employees created during the past Contract Year; total number and geographic
                                         location of full-time employees of Licensee at the end of such Contract Year;

  

		(b)	Dollar amount of new equity
                                         financing received by Licensee during the past Contract Year, and current capitalization,
                                         including number and class of outstanding securities;

 

		(c)	Location and square footage
                                         of facilities; and

 

		(d)	Other information required under
                                         Federal and state law.

  

This information shall
be treated as Licensee’s Confidential Information; provided that Licensor is entitled to combine such information with similar
information from other Licensor licensees and publicly report such combined aggregate information, without identifying Licensee’s
separate specific applicable numbers. If and when Licensee has more than two hundred (200) full-time employees, then no further
economic development reports will be required from Licensee.

 

		5.	Payment, Records, and
Audits

 

		5.1	Payments

All
amounts referred to in the Patent & Technology License Agreement are expressed in U.S. dollars without deductions for taxes,
assessments, fees, or charges of any kind. Each payment will reference the agreement number set forth at the beginning of the
Patent & Technology License Agreement. All payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee
to pay all wire transfer fees) payable to the payee identified in Section 18 of the Patent & Technology License Agreement
and sent to the payment and reporting contact in Section 18 (Notices) of the Patent & Technology License Agreement.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 21 of 39

    	Exhibit 10.4

    

  

		5.2	Sales Outside the U.S.

If any currency conversion
shall be required in connection with the calculation of payments hereunder, such conversion shall be made using the rate used
by Licensee for its financial reporting purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent)
or, in the absence of such rate, using the average of the buying and selling exchange rate for conversion between the foreign
currency and U.S. Dollars, for current transactions as reported in The Wall Street Journal on the last business day of
the Contract Quarter to which such payment pertains. Licensee may not make any tax withholdings from payments to Licensor, but
Licensor agrees to supply to Licensee, upon written request, appropriate evidence from appropriate U.S. governmental agencies
showing that Licensor is a resident of the United States of America for purposes of the U.S. income tax laws and is tax-exempt
under such income tax laws.

 

		5.3	Late Payments

Amounts that are not paid
when due will accrue a late charge from the due date until paid, at a rate equal to 1.0% per month (or the maximum allowed by
law, if less).

 

		5.4	Records

For a period of six (6)
years after the Contract Quarter to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will
each keep complete and accurate records of their Sales, Net Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration
in sufficient detail to enable such payments to be determined and audited.

 

		5.5	Auditing

Licensee and its Affiliates
will permit Licensor or its representatives, at Licensor’s expense, to periodically examine books, ledgers, and records
during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least thirty (30) days advance
notice, to the extent necessary to verify any payment or report required under the Agreement. For each Sublicensee, Licensee shall
obtain such audit rights for Licensor or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an
audit of the Sublicensee’s records upon Licensor’s request, and Licensee will furnish to Licensor a copy of the findings
from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5
in any calendar year. If any amounts due Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount
of such underpayment plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to
or greater than 5% of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits
may, at Licensor’s sole discretion, consist of a self-audit conducted by Licensee at Licensee’s expense and
certified in writing by an authorized officer of Licensee. All information examined pursuant to this Section 5.5 shall be
deemed to be the Confidential Information of the Licensee.

 

		6.	Patent Expenses and Prosecution

 

		6.1	Patent Expenses

Licensee shall pay for
all past documented, out-of-pocket expenses incurred by Licensor for filing, prosecuting, defending and maintaining Patent Rights
and related patent searches through the Effective Date of the Agreement, including those identified in Section 3.1(a) of the Patent
& Technology License Agreement, and all such future expenses incurred by Licensor, for so long as, and in such countries as
the Agreement remains in effect. Licensee will pay all patent expenses (except for the payment called for under Section 3.1(a)),
including past expenses that have not been invoiced as of the date indicated in Section 3.1(a) of the Patent & Technology
License Agreement and future expenses, within thirty (30) days after Licensee’s receipt of an invoice. At the election of
Licensor, Licensee will either pay Prosecution Counsel directly for patent expenses or will reimburse Licensor for such patent
expenses. Patent expense payment delinquencies (whether owed directly to Prosecution Counsel or to Licensor) will be considered
a payment default under Section 7.3(a).

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 22 of 39

    	Exhibit 10.4

    

  

		6.2	Direction of Prosecution

Licensor will confer with
Licensee to develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that copies of all
documents prepared by the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review
and comment prior to filing, to the extent practicable under the circumstances. At its discretion, Licensor may allow Licensee
to instruct Prosecution Counsel directly, provided, that (a) Licensor will maintain final authority in all decisions regarding
the prosecution and maintenance of the Patent Rights, (b) Licensor may revoke this authorization to instruct Prosecution Counsel
directly at any time, and (c) the Prosecution Counsel remains counsel to the Licensor with an appropriate contract (and shall
not jointly represent Licensee unless requested by Licensee and approved by Licensor, and an appropriate engagement letter and
conflict waiver are in effect). If Licensee wishes to instruct Prosecution Counsel directly or change Prosecution Counsel, Licensee
may request to do so by following the Licensor’s procedures for such. Licensor reserves in its sole discretion the ability
to change Prosecution Counsel and to approve or disapprove any requested changes by Licensee. The Parties agree that they share
a common legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received
pursuant to this Section.

 

		6.3	Ownership

All patent applications
and patents will be in the name of Licensor (and any co-owner identified in Section 1 of the Patent & Technology License Agreement)
and owned by Licensor (and such co-owner, if any). No payments due under the Agreement will be reduced as the result of co-ownership
interests in the Patent Rights by Licensee or any other party.

 

		6.4	Foreign Filings

In addition to the U.S.,
the Patent Rights shall, subject to applicable bar dates, be pursued in such foreign countries as Licensee so designates in writing
to Licensor in sufficient time to reasonably enable the preparation of such additional filings, and in those foreign countries
in which Licensor has filed applications prior to the Effective Date. If Licensee does not choose to pursue patent rights in a
particular foreign country and Licensor chooses to do so, Licensee shall so notify Licensor and thereafter said patent application
or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. Licensor shall have
the right to make alternative arrangements with Licensee for upfront payment of foreign patent expenses.

 

		6.5	Withdrawal from Paying
Patent Costs

If at any time Licensee
wishes to cease paying for any costs for a particular Patent Right or for patent prosecution in a particular jurisdiction, Licensee
must give Licensor at least ninety (90) days prior written notice and Licensee will continue to be obligated to pay for the patent
costs which reasonably accrue during said notice period. Thereafter, said patent application or patent shall no longer be included
in the Patent Rights and Licensee shall have no further rights thereto.

 

		6.6	U.S. Patent and Trademark
Office Entity Size Status

Licensee represents that
as of the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark
Office is as set forth in Section 1 of the Patent & Technology License Agreement. Licensee will inform Licensor in writing
on a timely basis of any change in its U.S. Patent and Trademark Office entity size status.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 23 of 39

    	Exhibit 10.4

    

  

		7.	Term and Termination

 

		7.1	Term

Unless earlier terminated
as provided herein, the term of the Agreement will commence on the Effective Date and continue until the last date of expiration
or termination of the Patent Rights, or if Technology Rights are licensed and no Patent Rights are applicable, for a term of 20
years.

 

		7.2	Termination by Licensee

Licensee,
at its option, may terminate the Agreement by providing Licensor written notice of intent to terminate, which such termination
effective will be ninety (90) days following receipt of such notice by Licensor.

 

		7.3	Termination by Licensor

Licensor,
at its option, may immediately terminate the Agreement, or any part of Licensed Subject Matter, or any part of Field of Use, or
any part of Territory, or the exclusive nature of the license grant, upon delivery of written notice to Licensee of Licensor’s
decision to terminate, if any of the following occur:

 

		(a)	Licensee becomes in arrears in any
                                         payments due under the Agreement, and Licensee fails to make the required payment within
                                         thirty (30) days after delivery of written notice from Licensor; or

 

		(b)	Licensee is in breach of any non-payment
                                         provision of the Agreement, and does not cure such breach within ninety (90) days after
                                         delivery of written notice from Licensor;

 

		(c)	Licensor delivers notice to Licensee
                                         of three or more actual breaches of the Agreement in any 12-month period, even in the
                                         event that Licensee cures such breaches in the allowed period; or

 

		(d)	Licensee or its Affiliate or Sublicensee
                                         initiates any proceeding or action to challenge the validity, enforceability, or scope
                                         of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding
                                         or action.

 

		7.4	Other Conditions of Termination

The
Agreement will terminate:

 

		(a)	Immediately without the necessity
                                         of any action being taken by Licensor or Licensee, (i) if Licensee files a bankruptcy
                                         action or becomes bankrupt or insolvent, or (ii) Licensee’s Board of Directors
                                         elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its
                                         business operations, or (iv) Licensee makes an assignment for the benefit of creditors,
                                         or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver,
                                         assignee or trustee, whether by voluntary act of Licensee or otherwise; or

 

		(b)	At any time by mutual
written agreement between Licensee and Licensor.

 

		7.5	Effect of Termination

If
the Agreement is terminated for any reason:

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 24 of 39

    	Exhibit 10.4

    

  

		(a)	All rights and licenses of Sublicensees
                                         shall terminate upon termination of the Agreement; provided however, if the Sublicense
                                         Agreement is for all of the Field of Use for all of the Territory, and the Sublicensee
                                         is in good standing and agrees in writing to assume all of the obligations of Licensee
                                         and provides Licensor with written notice thereof within thirty (30) days after termination
                                         of the Agreement, then such Sublicense Agreement shall survive; and

 

		(b)	Licensee
                                         shall cease making, having made, distributing, having distributed, using, selling, offering
                                         to sell, leasing, loaning and importing any Licensed Products and performing Licensed
                                         Services by the effective date of termination; and

 

		(c)	Licensee
                                         shall tender payment of all accrued royalties and other payments due to Licensor as of
                                         the effective date of termination; and

 

		(d)	Nothing in the Agreement will be
                                         construed to release either Party from any obligation that matured prior to the effective
                                         date of termination; and

 

		(e)	The provisions of Sections 8 (Confidentiality),
                                         9 (Infringement and Litigation), 11 (Representations and Disclaimers), 12 (Limit of Liability),
                                         13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General
                                         Provisions) will survive any termination or expiration of the Agreement. In addition,
                                         the provisions of Sections 3 (Compensation), 4.1 (Quarterly Payment and Milestone Reports),
                                         5 (Payment, Records and Audits), and 6.1 (Patent Expenses), and 20.2 (Payment Schedule
                                         for Past Patent Expenses) shall survive with respect to all activities and payment obligations
                                         accruing prior to the termination or expiration of the Agreement.

 

		8.	Confidentiality

 

		8.1	Definition

“Confidential
Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and provided
by one Party to the other Party under the Agreement.

 

		8.2	Protection and Marking

Licensor and Licensee
each agree that all Confidential Information disclosed in tangible form, and marked “confidential” and forwarded to
one by the other, or if disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict
confidence by the receiving Party, (ii) is to be used by and under authority of the receiving Party only as authorized in the
Agreement, and (iii) shall not be disclosed by the receiving Party, its agents or employees without the prior written consent
of the disclosing Party or as authorized in the Agreement. Licensee has the right to use and disclose Confidential Information
of Licensor reasonably in connection with the exercise of its rights under the Agreement, including without limitation disclosing
to Affiliates, Sublicensees, potential investors, acquirers, and others on a need to know basis, if such Confidential Information
is provided under conditions which reasonably protect the confidentiality thereof. Each Party’s obligation of confidence
hereunder includes, without limitation, using at least the same degree of care with the disclosing Party’s Confidential
Information as it uses to protect its own Confidential Information, but always at least a reasonable degree of care.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 25 of 39

    	Exhibit 10.4

    

  

		8.3	Confidentiality of Terms
of Agreement

Each Party agrees not
to disclose to any third party the terms of the Agreement without the prior written consent of the other Party hereto, except
each Party may disclose the terms of the Agreement: (a) to advisors, actual or potential Sublicensees, acquirers or investors,
and others on a need to know basis, in each case, under appropriate confidentiality obligations substantially similar to those
of this Section 8; and (b) to the extent necessary to comply with applicable laws and court orders (including, without limitation,
Ohio Public Records laws, as may be amended from time to time, other open records laws, decisions and rulings, and securities
laws, regulations and guidance). If the Agreement is not for all fields of use, then Licensor may disclose the Field of Use to
other potential third party licensees. Notwithstanding the foregoing, the existence of the Agreement shall not be considered Confidential
Information.

 

		8.4	Disclosure Required by
Court Order or Law

If the receiving Party
is required to disclose Confidential Information of another Party hereto, or any terms of the Agreement, pursuant to the order
or requirement of a court, administrative agency, or other governmental body or applicable law, the receiving Party may disclose
such Confidential Information or terms to the extent required, provided that the receiving Party shall use reasonable efforts
to provide the disclosing Party with reasonable advance notice thereof to enable the disclosing Party to seek a protective order
and otherwise seek to prevent such disclosure. To the extent that Confidential Information so disclosed does not become part of
the public domain by virtue of such disclosure, it shall remain Confidential Information protected pursuant to Section 8.

 

		8.5	Copies

Each Party agrees not
to copy or record any of the Confidential Information of the other Party, except as reasonably necessary to exercise its rights
or perform its obligations under the Agreement, and for archival and legal purposes.

 

		8.6	Continuing Obligations

Subject to the exclusions
listed in Section 8.7, the Parties’ confidentiality obligations under the Agreement will survive termination of the Agreement
and will continue for a period of three (3) years thereafter.

 

		8.6	Exclusions

Information shall not
be considered Confidential Information of a disclosing Party under the Agreement to the extent that the receiving Party can establish
by competent written proof that such information:

 

		(a)	Was in the public domain
at the time of disclosure; or

 

		(b)	Later
                                         became part of the public domain through no act or omission of the recipient Party, its
                                         employees, agents, successors or assigns in breach of the Agreement; or

 

		(c)	Was
                                         lawfully disclosed to the recipient Party by a third party having the right to disclose
                                         it not under an obligation of confidentiality; or

 

		(d)	Was already known by the
recipient Party at the time of disclosure; or

 

		(e)	Was independently developed by the
                                         recipient Party without use of the disclosing Party’s Confidential Information.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 26 of 39

    	Exhibit 10.4

    

  

		8.8	Copyright Notice

The placement of a copyright
notice on any Confidential Information will not be construed to mean that such information has been published and will not release
the other Party from its obligation of confidentiality hereunder.

 

		9.	Infringement and Litigation

 

		9.1	Notification

If either Licensor’s
designated office for technology commercialization or Licensee becomes aware of any infringement or potential infringement of
Patent Rights, each Party shall promptly notify the other of such in writing.

 

		9.2	Licensee’s Enforcement
Rights

Licensee shall enforce
the Patent Rights against any infringement by a third party in the Field in the Territory.  Licensee shall be responsible
for payment of all fees and expenses associated with such enforcement incurred by Licensee and incurred by Licensor
in providing cooperation or joining as a party as provided in Section 9.4.  Any monetary recovery for actual damages or punitive
damages, in excess of Licensee’s documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed
by Licensee to Licensor under this Section 9.2 shall be shared by Licensee with Licensor in the same manner as Non-Royalty Sublicensing
Consideration.

 

		9.3	Licensor’s Enforcement
Rights

If Licensee does not file
suit within six (6) months after a written request by Licensor to initiate an infringement action, then Licensor shall have the
right, at its sole discretion, to bring suit to enforce any Patent Right licensed hereunder against the infringing activities,
with Licensor retaining all recoveries from such enforcement. If Licensor pursues such infringement action, Licensor may, as part
of the resolution of such efforts, grant non-exclusive license rights to the alleged infringer notwithstanding Licensee’s
exclusive license rights.

 

		9.4	Cooperation between Licensor
and Licensee

In any infringement suit
or dispute, the Parties agree to cooperate fully with each other. At the request of the Party bringing suit, the other Party will
permit reasonable access after reasonable advance notice to all relevant personnel, records, papers, information, samples, specimens,
etc., during regular business hours.

 

If it is necessary to
name Licensor as a party in such action, then Licensee must first obtain Licensor’s and the Ohio Attorney General’s
prior written permission, which permission shall not be unreasonably withheld, provided that Licensor shall have reasonable prior
input on choice of counsel on any matter where such counsel represents Licensor, and Licensee and such counsel agree to follow
all required procedures of the Ohio Attorney General regarding retention of outside counsel for state entities.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 27 of 39

    	Exhibit 10.4

    

  

		9.5	Contest
                                         of Validity

 

(a)            In
the event Licensee or its Sublicensee(s) (or a third party on its behalf) files any action contesting the validity or enforceability
of any Patent Rights and the provision in Section 7.3(d) is unenforceable, the Licensee (or its Sublicensee(s), if such Sublicensee
filed the action) shall pay a royalty rate of one and a half (1.5) times the royalty rate specified in Section 3.2 for all Net
Sales. Moreover, should the outcome of such contest determine that any claim of the Patent Rights challenged is both valid and
would be infringed by a Licensed Product, Licensed Process, or Licensed Service sold by Licensee (or its Sublicensee(s) if such
Sublicensee filed the action), if not for the license granted by this Agreement, Licensee (or its Sublicensee(s), if such Sublicensee
filed the action) shall thereafter, and for the remaining term of this Agreement, pay a royalty rate of two (2) times the royalty
rate specified in Section 3.2 for all Net Sales.

 

(b)            In
the event that Licensee or its Sublicensee(s) contests the validity or enforceability of any Patent Rights during the term of
this Agreement, Licensee agrees (and shall require its Sublicensee(s) to agree) to pay to Licensor all royalties due under the
Agreement during the period of challenge. For the sake of clarity, such amounts shall not be paid into any escrow or other account,
but directly to Licensor, and shall not be refunded.

 

(c)            In
the event that a validity or non-infringement challenge of any Patent Rights brought by Licensee is successful, Licensee shall
have no right to recoup any royalties paid before or during the period challenge.

  

		10.	Export Compliance

 

10.1         Licensee shall
observe all applicable United States and foreign laws and regulations with respect to the research, development, manufacture,
marketing and transfer of Licensed Products and related technical data, including, without limitation, the International Traffic
in Arms Regulations (ITAR) and the Export Administration Regulation (collectively, the “Export Laws”). To this end,
Licensee shall take all actions necessary to comply with the Export Laws. Licensee hereby represents and covenants that Licensee:

 

		(i)	Is neither a national of nor controlled
                                         by a national of any country to which the United States prohibits the export or re-export
                                         of goods, services, or technology;

 

		(ii)	Is not a person specifically
                                         designated as ineligible to export from the United States or deal in U.S.-origin goods,
                                         services, or technologies;

 

		(iii)	Shall not export or re-export,
                                         directly or indirectly, any goods, services, or technology, to any country or person
                                         (including juridical persons) to which the United States prohibits the export of goods,
                                         technology or services; and

 

		(iv)	In the event that a United States
                                         government license or authorization is required for an export or re-export of goods,
                                         services, or technology (including technical information acquired from Licensor under
                                         this Agreement and/or any products created by using such technical information or any
                                         part thereof), the Licensee shall obtain any necessary United States government license
                                         or other authorization prior to undertaking the export or re-export.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 28 of 39

    	Exhibit 10.4

    

  

Licensee shall include
a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party wholesalers and distributors,
and physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties comply with
all then-current applicable export laws and regulations and other applicable laws and regulations.

 

		11.	Representations and Disclaimers

 

		11.1	Licensor Representations

Except for the rights,
if any, of the Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge of
Licensor’s designated office for technology commercialization (i) Licensor is the owner or agent of the entire right, title,
and interest in and to Patent Rights (other than the right, title and interest of any joint owner identified in Section 1 of the
Patent & Technology License Agreement), (ii) Licensor has the right to grant the license and sublicense hereunder, and (iii)
Licensor has not knowingly granted and will not knowingly grant licenses or other rights under the Patent Rights that are in conflict
with the terms and conditions in the Agreement.

 

		11.2	Government Rights

Licensee understands that
Licensed Subject Matter may have been developed under a funding agreement with Government and, if so, that Government may have
certain rights relative thereto. The Agreement is made subject to the Government’s rights under any such agreement (NIH
reference number L-003-2009) and under any applicable Government law or regulation. To the extent that there is a conflict between
any such agreement, such applicable law or regulation and the Agreement, the terms of such Government agreement, and applicable
law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations, Licensed Products
used or Sold in the U.S. will be manufactured substantially in the U.S., unless a written waiver is obtained in advance from the
U.S. Government.

 

		11.3	Licensor Disclaimers

EXCEPT AS SPECIFICALLY
SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY OR FITNESS
FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF
DEVELOPMENT, PATENTABILITY, NONINFRINGEMENT, AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY
CLAIM OR PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS
OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD OF USE. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS
CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE
PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS, OR THE TECHNOLOGY RIGHTS SPECIFICALLY DESCRIBED
HEREIN.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 29 of 39

    	Exhibit 10.4

    

 

		11.4	Licensee Representation

By execution of the Agreement,
Licensee represents, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees
to enter into the Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect
to all items and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the
Agreement; and (c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to
adequately conduct the due diligence, and (c) that Licensee accepts all risks inherent herein. Licensee represents that it is
a duly organized, validly existing entity of the form indicated in Section 1 of the Patent & Technology License Agreement,
and is in good standing under the laws of its jurisdiction of organization as indicated in Section 1 of the Patent & Technology
License Agreement, and has all necessary corporate or other appropriate power and authority to execute, deliver and perform its
obligations hereunder.

 

		12.	Limit of Liability

 

IN NO EVENT SHALL LICENSOR,
OSU, OR THEIR INVENTORS, OFFICERS, EMPLOYEES, STUDENTS, TRUSTEES, AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT,
SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS
OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS
OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (SECTION 13) OR
FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LICENSOR’S INTELLECTUAL PROPERTY RIGHTS, LICENSEE WILL NOT BE LIABLE TO
LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS
OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR
SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.

 

		13.	Indemnification

 

		13.1	Indemnification Obligation

Licensee agrees to hold
harmless, defend and indemnify Licensor, OSU, and their officers, employees, students, inventors, trustees, agents, and consultants
(“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties,
fines, losses, costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation)
(collectively “Liabilities”) resulting from claims or demands brought by third parties against an Indemnified Party
on account of any injury or death of persons, damage to property, or any other damage or loss arising out of or in connection
with the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third
party wholesalers or distributors, or physicians, hospitals or other healthcare providers who purchase a Licensed Product, of
the rights granted hereunder. Licensee shall have no responsibility or obligation under the section for any Liabilities to the
extent caused by the gross negligence or willful misconduct by Licensor.

 

		14.	Insurance

 

		14.1	Insurance Requirements

Prior to any Licensed
Product being used or Sold (including for the purpose of obtaining Regulatory Approval), and prior to any Licensed Service being
performed by Licensee, an Affiliate, or by a Sublicensee, and for a period of five years after the Agreement expires or is terminated,
Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable
and appropriate amounts for the Licensed Product being used or Sold or the Licensed Service being performed. Licensee shall use
commercially reasonable efforts to have Licensor, its officers, employees named as additional insureds. Such commercial general
liability insurance shall provide, without limitation: (i) product liability coverage; (ii) broad form contractual liability
coverage for Licensee’s indemnification under the Agreement; and (iii) coverage for litigation costs.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 30 of 39

    	Exhibit 10.4

    

  

		14.2	Evidence of Insurance
and Notice of Changes

Upon request by Licensor,
Licensee shall provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written
notice of at least sixty (60) days prior to Licensee cancelling, not renewing, or materially changing such insurance.

 

		15.	Assignment

 

The Agreement may not
be assigned by Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld. For any
permitted assignment to be effective, (a) Licensee must be in good standing under this Agreement, (b) the Licensee must pay Licensor
the assignment fee pursuant to Section 3.1(f), and (c) the assignee must assume in writing (a copy of which shall be promptly
provided to Licensor) all of Licensee’s interests, rights, duties and obligations under the Agreement and agree to comply
with all terms and conditions of the Agreement as if assignee were an original Party to the Agreement.

 

		16.	Governmental Markings

 

		16.1	Patent Markings

Licensee agrees that all
Licensed Products Sold by Licensee, Affiliates, and Sublicensees will be marked in accordance with each country’s patent
marking laws, including Title 35, U.S. Code, in the United States.

 

		16.2	Governmental Approvals
and Marketing of Licensed Products and or Licensed Services

Licensee will be responsible
for obtaining all necessary governmental approvals for the development, production, distribution, Sale, and use of any Licensed
Product or performance of any Licensed Service, at Licensee’s expense, including, without limitation, any safety studies.
Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use and the quality control
for any Licensed Product or Licensed Service.

 

		16.3	Foreign Registration
and Laws

Licensee agrees to register
the Agreement with any foreign governmental agency that requires such registration; and Licensee will pay all costs and legal
fees in connection with such registration. Licensee is responsible for compliance with all foreign laws affecting the Agreement
or the Sale of Licensed Products and Licensed Services to the extent there is no conflict with United States law, in which case
United States law will control.

 

		17.	Use of Name

 

Licensee will not use
the name, trademarks or other marks of Licensor or OSU without the advance written consent of Licensor or OSU. Licensor or OSU
may use Licensee’s name and logo for annual reports, brochures, website and internal reports without prior consent.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 31 of 39

    	Exhibit 10.4

    

 

		18.	Notices

 

Any notice or other
communication of the Parties required or permitted to be given or made under the Agreement will be in writing and will be deemed
effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth
in Section 18 of the Patent & Technology License Agreement (or as changed by written notice pursuant to this Section 18).
Notices required under the Agreement may be delivered via E-mail provided such notice is confirmed in writing as indicated.

 

Notices shall be provided
to each Party as specified in the “Contact for Notice” address set forth in Section 18 of the Patent & Technology
License Agreement. Each Party shall update the other Party in writing with any changes in such contact information.

 

		19.	General Provisions

 

		19.1	Binding Effect

The Agreement is binding
upon and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and
permitted successors in interest.

 

		19.2	Construction of Agreement

Headings are included
for convenience only and will not be used to construe the Agreement. The Parties acknowledge and agree that both Parties substantially
participated in negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement
shall not be construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement.

 

		19.3	Counterparts and Signatures

The Agreement may be executed
in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and
the same instrument. A Party may evidence its execution and delivery of the Agreement by transmission of a signed copy of the
Agreement via facsimile or email. In such event, the Party shall promptly provide the original signature page(s) to the other
Party.

 

		19.4	Compliance with Laws

Licensee will comply with
all applicable federal, state and local laws and regulations, including, without limitation, all export laws and regulations.

 

		19.5	Governing Law

The Agreement will be
construed and enforced in accordance with laws of the State of Ohio, without regard to choice of law and conflicts of law principles.

 

		19.6	Modification

Any modification of the
Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification
will be made by email communications.

 

		19.7	Severability

If any provision hereof
is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid,
legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions
hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions
of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of the Agreement
remains enforceable.

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 32 of 39

    	Exhibit 10.4

    

  

		19.8	Third Party Beneficiaries

Nothing in the Agreement,
express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties, OSU and their
permitted successors and assigns. However, if there is a joint owner of any Patent Rights identified in Section 1 of the Patent
& Technology License Agreement (other than Licensee), then Licensee hereby agrees that the following provisions of these Terms
and Conditions extend to the benefit of the co-owner identified therein (excluding the Licensee to the extent it is a co-owner)
as if such co-owner was identified in each reference to the Licensor: the retained rights under clause (b) of Section 2.1; Section
11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section 13 (Indemnification); Section 14.1 (Insurance Requirements);
Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable).

 

		19.9	Waiver

Neither Party will be
deemed to have waived any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay
or omission of a Party in exercising or enforcing a right or remedy under the Agreement shall operate as a waiver thereof.

 

		19.10	Sovereign Immunity

Nothing in the Agreement
shall be deemed or treated as any waiver of OSU’s sovereign immunity.

 

		19.11	Entire Agreement

The Agreement constitutes
the entire Agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements,
representations and understandings relative to such matters.

 

		19.12	Claims Against Licensor
for Breach of Agreement

Licensee acknowledges
that any claim for breach of the Agreement asserted by Licensee against Licensor shall be brought in a court of competent jurisdiction
in Ohio and this is Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches of the Agreement
by Licensor.

 

		19.13	Grant of Security Interest

Licensee hereby grants
to Licensor a security interest in and to Licensee's rights under the Patent & Technology License Agreement, as collateral
security for the payment by Licensee of any and all sums which may be owed from time to time by Licensee to Licensor. Licensor
shall have all rights of a secured party as specified in the Uniform Commercial Code relative to this security interest and the
enforcement thereof. Licensee hereby authorizes Licensor to file with the appropriate governmental agencies appropriate UCC-1
financing statements to evidence this security interest.

 

—
END OF EXHIBIT A —

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 33 of 39

    	Exhibit 10.4

    

  

EXHIBIT
B

COMMERCIALIZATION
PLAN

 

EXIHIBIT
C

PATENT
APPLICATIONS

 

	TECH ID	APP. Title	TERR.	PAT. APP#	Filing Date
	2006-008

        Joint
        with NIH
	MicroRNA-Based
    Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer	PCT	PCT/US2007/000103	01/03/2007
	2006-008-06

        Joint
        with NIH
	 	US	7,943,318

        ISSUED
	07/03/2008
	2006-008-03

        Joint
        with NIH
	 	AU	2007205234

        ISSUED
	07/03/2008
	2006-008-04

        Joint
        with NIH
	 	CA	2,633,674	06/18/2008
	2006-008-05

        Joint
        with NIH
	 	EU	07717734.3	07/03/2008
	2006-008-07

        Joint
        with NIH
	 	CN	ZL200780006750.8

        ISSUED
	08/26/2008
	2006-008-08

        Joint
        with NIH
	 	JP	2008-549549	07/07/2008
	2006-008-10

        Joint
        with NIH
	 	JP	59-3172050	09/08/2008
	2006-008-12

        Joint
        with NIH
	 	US	8,367,710

        ISSUED
	03/30/2011
	2006-008-13

        Joint
        with NIH
	 	US	8,377,637

        ISSUED
	03/30/2011

         

	2006-008-16

        Joint
        with NIH
	 	EU	12165748.0

        ALLOWED
	04/26/2012
	2006-008-17

        Joint
        with NIH
	 	EU	12165740.7	04/26/2012
	2006-008-18

        Joint
        with NIH
	 	 	12165478.0	04/26/2012
	2006-008-19

        Joint
        with NIH
	 	AU	2012-238336	12/18/2012
	2006-008-020

        Joint
        with NIH
	 	AU	2007-205234	10/11/2012

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 34 of 39

    	Exhibit 10.4

    

  

	2006-008-021

        Joint
        with NIH
	 	CN	CN1210312507.1	03/21/2013
	2006-008-33

        Joint
        with NIH
	 	 	2011-552098	 
	2006-009	Compositions
    and Methods for the Diagnosis and Therapy of BCL-2 Associated Cancers	au	2006291165

         

        ALLOWED

         
	09/11/06
	2006-009	 	ca	2,621,441	09/11/06
	2006-009	 	cn	ZL200680039776.8

         

        ISSUED

         
	09/11/06
	2006-009	 	cn	2012-10380806.9	10/10/12
	2006-009	 	ep	06814375.9	09/11/06
	2006-009	 	jp	2008-531200	09/11/06
	2006-009	 	jp	2013-081761	09/11/06
	2006-009	 	us	11/991,773

         

        allowed

         
	05/14/08
	2006-138	MicroRNA-Based
    Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers	PCT	PCT/US2007/00159	01/03/2007
	2006-138-03	 	CA	2,633,754

         

        ALLOWED

         
	01/03/2007
	2006-138-58	 	CA	2811486  	03/29/2013
	2006-138-07	 	JP	2008-549555	01/03/2007
	2006-138-50	 	JP	2012-183280	09/08/2012

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 35 of 39

    	Exhibit 10.4

    

  

	2006-138-04	 	AU	2007-205163

         

         

         
	07/03/2008
	2006-138-09	 	HK	09108431.1	01/03/2007
	2006-138-12	 	CN	2007-80005821.2	01/03/2007
	2006-138-06	 	US	8,148,069

         

        ISSUEd

         
	07/03/2008
	2006-138-11	 	US	13/405,517	02//27/2012
	2006-138-12	 	US	13/405,533	02//27/2012
	2006-138-13	 	US	13,/405,543	02/27/2012
	2006-138-18	 	US	13/406,618	02/28/2012
	2006-138-24	 	US	13/407,894	02/29/2012
	2006-138-05	 	EU	07717903.4	01/03/2007
	2006-138-57	 	EU	12151246.8	03/05/2012
	2006-138-55	 	EU	12154298.9	01/03/2007
	2006-138-56	 	EU	12154300.3	01/03/2007
	2006-138-47	 	EU	12154307.8	01/03/2007
	2006-138-45	 	EU	12154326.8

         

        ******

         
	03/05/2012
	2006-138-27	 	EU	12154345.8	03/01/2012
	2006-138-33	 	EU	12154351.6	03/01/2012
	 	 	 	 	 
	2007-028	Ultraconserved
    Regions Encoding ncRNAs	AU	2008283997	02/11/10

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 36 of 39

    	Exhibit 10.4

    

  

	2007-028	 	CA	2,695,514	02/03/10
	2002007-028	 	CN	2008-80108689.2	08/04/08
	2007-028	 	EP	08782609.5	02/04/10
	2007-028	 	JP	2010-519269	01/28/10
	2007-028	 	US	12/672,014 

        ALLOWED

         
	02/03/10
	2007-030	Methods
        for Identifying Fragile Histidine Triad (Fhit) Interaction and Uses Thereof

        (this
        application has broad claims that could be amended to include lung and colon)
	AU	2008316577 

        *****

         
	04/27/10
	2007-030	 	CA	2,703,707 

        *****

         
	04/23/10
	2007-030	 	CN	200880119206.9 

        *****

         
	10/27/08
	2007-030	 	EP	08841700.1

    *****	04/26/10
	2007-030	 	JP	2010-531311 

        *****

         
	04/26/10
	2007-030	 	US	12/739,541 

        *****

         
	02/25/11
	 	 	 	 	 
	2007-159-06	METHODS
    FOR REVERTING METHYLATION BY TARGETING DNMT3A AND DNMT3B	AU	2008282318	07/30/2008
	2007-159-03	 	US	8,367,632 

        ISSUED

         
	02/01/2012

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 37 of 39

    	Exhibit 10.4

    

  

	2007-159-08	 	EU	08796821.0	07/30/2008
	2007-159-09	 	CA	2695184	01/29/2010
	2007-159-10	 	CN	200880108625.2	03/25/2010
	2007-159-11	 	JP

         

         

         
	2010-520,144	01/28/2010
	2007-159-12	 	US	13/740,345	01/14/2013
	2010-079-02	Materials
    and methods useful for affecting tumor cell growth, migration and invasion	AU	2010321555	05/15/2012
	2010-079-04	 	CA	2781547	05/22/2012
	2010-079-06	 	US	13/511,474	05/23/2012
	2010-079-07	 	CN	201080059339.9	07/12/2012
	2010-079-08	 	JP	2012-541156	09/26/2012
	2010-079-08	 	EU	10832355.1	08/21/2012
	2010-126	Materials
    and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155	au	2011232669	09/24/12
	2010-126	 	CA	2,794,142	09/24/12
	2010-126	 	CN	2011-80022637.5	09/24/12
	2010-126	 	EP	11760035.3	09/24/12

 

    	{00182041-1}Licensee:  MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 38 of 39

    	Exhibit 10.4

    

  

	2010-126	 	JP	2013-502642	09/26/12
	2010-126	 	US	13/637,490	11/15/12
	2011-137	Mutator
    activity induced by microRNA-155 links inflammation and cancer	PCT	PCT/US2012/028016

         ******

         
	03/07/12
	2011-137	 	US	13/414,084

        

        ******

         
	03/07/12
	2012-066	Methods
    and Compositions Related to miR-21 & miR-29a and Cancer Metastasis	PCT	PCT/US2012/069484

         *****

         
	12/13/12
	2012-111	miRNAs
    USEFUL TO REDUCE LUNG CANCER TUMORIGENESIS AND CHEMOTHERAPY RESISTANCE AND RELATED COMPOSITIONS AND METHODS	PCT	PCT/US2012/068736	12/10/2012
	2013-072	Use
    of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation	Prov.	61/704,542	09/23/2012

  

    	{00182041-1}Licensee: MicroLin Bio
Licensor: Ohio State Innovation Foundation	CONFIDENTIAL
EXHIBIT A	Exclusive License (Life Sciences)
Page 39 of 39

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]